|[January 18, 2013]
S&P Capital IQ Initiates Coverage on TONIX Pharmaceuticals Holding Corp. in Standard & Poor's Factual Stock Reports
NEW YORK --(Business Wire)--
S&P Capital IQ announced today that it has commenced Standard & Poor's
Factual Stock Report coverage on TONIX
Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp. (OTCQB: TNXP) develops prescription
medications for challenging disorders of the central nervous system
("CNS"). The company targets conditions characterized by significant
unmet medical needs, inadequate existing treatment options, and high
dissatisfaction among both patients and physicians. Tonix's core
technology improves the quality of sleep in patients with chronic pain
TNXP is focused on developing new pharmaceutical products for CNS
conditions that may be safer and more effective than currently available
treatments. Tonix uses ongoing advances in science and medicine to
search for potential therapeutic solutions among already existing
prescription pharmaceutical agents that have been successfully used in
patients for other conditions. The company creates new dose formulations
for these agents with the intent to developing products that are
optimized for the new therapeutic uses or indications that Tonix targets.
TNXP's most advanced product candidate, sublingual TNX-102 ("TNX-102
SL") for FM and post-traumatic stress disorder ("PTSD"), is a novel
dosage formulation of cyclobenzaprine, the active ingredient in two U.S.
FDA-approved muscle relaxants. In 2013, TNX-102 SL is expected to enter
Phase 3 fo FM and Phase 2 for PTSD. The company is working to optimize
the dose and formulation of TNX-102 to treat FM safely.
Tonix Pharmaceuticals Holding Corp. was founded in 2007.
Standard & Poor's Factual Stock Report coverage on TONIX Pharmaceuticals
Holdings Corp. will also be accessible on an ongoing basis to the
investment community by scores of buy-side institutions and sell-side
firms that utilize S&P Capital IQ research and information platforms
daily. Millions of self-directed investors also have access to the
report via their e-brokerage accounts. Please visit http://www.tonixpharma.com/
for additional information.
About Standard & Poor's Factual Stock Reports
Currently profiling approximately 500 issuers, Standard & Poor's Factual
Stock Reports, produced by S&P Capital IQ, increase market awareness of
issuers in the investment community with insightful commentary and key
statistics and information. Standard & Poor's Factual Stock Reports
provide factual research coverage about company fundamentals and
business prospects, thereby enabling information about covered companies
to reach a wide investor audience of Buy and Sell-side investors.
Updated weekly with the latest pricing, trading volume, and other data,
the reports include recent developments, a financial review, key
operating information, industry and peer comparisons, institutional
holdings analysis, Street Consensus and opinions, performance charts,
business summary, fundamental data, and news. Because coverage of these
reports is underwritten by the issuer, S&P Capital IQ does not offer
investment opinions concerning the advisability of investing in these
Standard & Poor's Factual Stock Reports are produced separately from any
other analytic activity of S&P Capital IQ or related organizations. S&P
Capital IQ does not trade on its own account.
About S&P Capital IQ
S&P Capital IQ, a business line of The McGraw-Hill Companies (NYSE:MHP),
is a leading provider of multi-asset class and real time data, research
and analytics to institutional investors, investment and commercial
banks, investment advisors and wealth managers, corporations and
universities around the world. We provide a broad suite of capabilities
designed to help track performance, generate alpha, and identify new
trading and investment ideas, and perform risk analysis and mitigation
strategies. Through leading desktop solutions such as the S&P Capital
IQ, Global Credit Portal and MarketScope Advisor desktops; enterprise
solutions such as S&P Capital IQ Valuations, and Compustat; and research
offerings, including Leveraged Commentary & Data, Global Markets
Intelligence, and company and funds research, S&P Capital IQ sharpens
financial intelligence into the wisdom today's investors need. For more
information visit www.spcapitaliq.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130118005481/en/
[ Back To Technology News's Homepage ]